CG Oncology, Inc. (CGON)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CG Oncology: Circling Back After Huge Rally
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CG Oncology, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 102 | $3,180.5 | $7,261.38 | $4,080.88 | 128.31% |
| NA Nizar Araji National Bank Of Canada /FI/ | 3 | $213.15 | $225.3 | $12.15 | 5.7% |
| BG Bart Gancher Intech Investment Management LLC | 16,212 | $563,288.99 | $1.22M | $654,232.18 | 116.15% |
 Joseph Castro Nuveen LLC | 188,420 | $7.41M | $14.43M | $7.02M | 94.72% |
 Richard Slavik Newbridge Financial Services Group Inc. | 500 | $33,840 | $37,515 | $3,675 | 10.86% |
CG Oncology, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GR Gregory Renza Truist Securities | 53.39 | $3,693.67 | $3,877.52 | $183.85 | 4.98% |
CG Oncology, Inc. (CGON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CG Oncology, Inc. ever had a stock split?
CG Oncology, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Arthur Kuan CEO | NASDAQ (NGS) Exchange | 156944100 CUSIP |
| US Country | 142 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CG Oncology, Inc. operates as an oncolytic immunotherapy entity dedicated to the creation and commercialization of pioneering bladder-sparing treatments designed for individuals battling bladder cancer. The inception of the company traces back to 2010, and it originally bore the name Cold Genesys, Inc. before rebranding to CG Oncology, Inc. in June 2020. Stationed in Irvine, California, CG Oncology has embarked on a mission to offer novel therapeutic avenues to improve the outcomes and lives of patients with bladder cancer.
Products and Services
CG Oncology is at the forefront of developing a portfolio of innovative treatments for various stages of bladder cancer, including:
- BOND-003: Specifically designed for high-risk patients who do not respond to the bacillus Calmette-Guerin (BCG) immunotherapy for non-muscle invasive bladder cancer (NMIBC). This product represents CG Oncology's commitment to providing alternatives to those with limited treatment options.
- CORE-001: A novel approach combining cretostimogene with pembrolizumab, tailored for high-risk BCG-unresponsive NMIBC patients. This combination therapy underscores the potential benefits of immunotherapy in treating bladder cancer by enhancing patients' immune responses against cancer cells.
- CORE-002: Targeting a more invasive stage of the disease, CORE-002 involves the combination of cretostimogene with another checkpoint inhibitor, nivolumab. This product is aimed at treating muscle-invasive bladder cancer, offering hope for individuals confronting this aggressive cancer form.
- PIVOT-006: Represents a monotherapy with cretostimogene for patients with intermediate-risk NMIBC following the surgical procedure known as transurethral resection of the bladder tumor. This therapy provides a treatment option aiming at reducing the recurrence of bladder cancer in this specific patient group.
- CORE-008: Developed for the treatment of high-risk NMIBC patients, including those who have been exposed to BCG as well as BCG-naïve patients. This product emphasizes CG Oncology's dedication to addressing the needs of a broad patient population facing NMIBC challenges.
